Monitoring of immune mechanisms of pathogenesis and efficiency of immune therapy in children with various phenotypes of bronchial asthma

  • Authors: Prosekova EV1, Sitdikova TS1,2, Zhdanova OL3
  • Affiliations:
    1. Federal State Budgetary Educational Institution of Higher Education «Pacific State Medical University» of the Ministry of Healthcare of the Russian Federation
    2. Regional State Budgetary Healthcare Institution «Vladivostok Clinical and Diagnostic Centre»
    3. FGBUN «Institute of Automation and Control Processes» of the Far Eastern Branch of the Russian Academy of Sciences
  • Issue: Vol 15, No 3 (2018)
  • Pages: 59-67
  • Section: Articles
  • URL: https://rusalljournal.ru/raj/article/view/152
  • DOI: https://doi.org/10.36691/RJA152
  • Cite item
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract


Background. Peculiarities of the disease and effectiveness of therapy depend on changes in availability and functions of effector immunocompetent cells and cytokine profile. Purpose. To study the peculiarities of immune pathogenetic mechanisms of virus-induced and allergen-induced bronchial asthma phenotypes in children in order to justify the use of immune therapy and to analyze it’s effectiveness. Materials and methods. We have performed an integrated assessment of immunological parameters in 120 children at the age of 3-11 y.o. with virus-induced and allergen-induced phenotypes of bronchial asthma (BA) and in 30 healthy children. Withdrawal criteria: severe BA, immune therapy during preceding 6 months. We used flow flow cytometer COULTER EPICS XL (Beckman Coulter Inc.) for identification of venous blood cells, CYTOKINE-STIMUL-BEST sets (Vektor-Best JSC, Novosibirsk) for levels of spontaneous and mitogen-induced production of cytokines identification. The immunological effectiveness of treatment was analyzed in the open parallel prospective study using random sampling technique in subgroups on the basis of treatment regimen. Statistical data processing was performed by «Statistica 10» program with critical significance level p<0,05, correlations were analyzed using Spearman rank correlation coefficient, clustering with nonparametric analysis of variance «Kruskal-Wallis ANOVA». Results. Children with various phenotypes of BA demonstrated discrepancies between impairments of availability, proliferation, differentiation and functional activity of immunocompetent cells and cytokine production. The imbalance of cytokine production and impairments of availability and functioning of immunocompetent cells remained unchanged after treatment by inhaled glucocorticoids. When bacterial lysate was added to therapy the normalization of parameters of cellular immune response was observed in patients with virus-induced BA. When glucosaminylmuramyl dipeptide was administered, the recovery of the cells’ capacity for production of spontaneous and mitogen-induced IFN-y was noted in children with allergen-induced phenotype of the disease. Conclusion. Immune pathogenetic mechanisms of virus-induced and allergen-induced BA in children with different immune mechanisms of the disease phenotype justifies individual immunotropic therapy use.

Restricted Access

E V Prosekova

Federal State Budgetary Educational Institution of Higher Education «Pacific State Medical University» of the Ministry of Healthcare of the Russian Federation

Email: pros.ev@mail.ru

T S Sitdikova

Federal State Budgetary Educational Institution of Higher Education «Pacific State Medical University» of the Ministry of Healthcare of the Russian Federation; Regional State Budgetary Healthcare Institution «Vladivostok Clinical and Diagnostic Centre»

O L Zhdanova

FGBUN «Institute of Automation and Control Processes» of the Far Eastern Branch of the Russian Academy of Sciences

  1. Agache С., Akdis C., Jutel M., Virchov JS. Untangling asthma phenotypes and endotypes. European J. of Allergy and Clinical Immunology. 2012; 67: 835-846.
  2. Akdis CA. The underlying mechanisms in allergy. In: Akdis CA, Agache I. EAACI Global Atlas of Allergy. Zurich: European Academy of Allergy and Clinical Immunology. Switzerland. 2014: 39-42.
  3. Poulsen LK. Cytokines in allergy. EAACI Global Atlas of Allergy. Zurich: European Academy of Allergy and Clinical Immunology. Switzerland. 2014: 69-70.
  4. Akdis CA. Global Atlas of Asthma. Zurich: EAACI European Academy of Allergy and Clinical Immunology. Switzerland. 2011: 196.
  5. Кудрявцев ИВ, Борисов АГ, Кробинец ИИ, Савченко АА, Серебрякова МК, Полевщиков А.В. Анализ уровня экспрессии CD56 и CD57 цитотоксическими Т-лимфо-цитами различного уровня дифференцировки. Тихоокеанский медицинский журнал. 2015; (2): 30-35
  6. Литвинова ЛС, Гуцол АА, Сохоневич НА, Кофанова КА, Хазиахматова ОГ, Шуплецова В.В. Основные поверхностные маркеры функциональной активности Т-лимфоцитов. Медицинская иммунология. 2014; (1): 7-26
  7. Горячкина ЛА, Битеева ДВ, Фомина Д.С. Основные маркеры нейтрофильного воспаления при бронхиальной астме тяжелого течения. Российский Аллергологический Журнал. 2012; (1): 21-28
  8. Ненашева Н.М. Фенотипы бронхиальной астмы и выбор терапии. Практическая пульмонология. 2014; (2): 2-11 [Nenasheva NM. Fenotipi bronkhialnoj astmy i vybor terapii [Phenotypes of bronchial asthma and choice of therapy]. Prakticheskaya pulmonologiya. 2014; (2): 2-11 (In Russ.)].
  9. Мицкевич С.Э. Фенотипы бронхиальной астмы у детей и дифференцированная тактика диагностики и лечения. Вестник Челябинского государственного университета. 2014; 4(333): 79-85
  10. Fitzpatrick AM, Baena-Cagnani CE, Bacharier LB. Severe Asthma in Childhood: Recent Advances in Phenotyping and Pathogenesis.Current Opinion in Allergy and Clinical Immunology. 2012; 12: 193-201.
  11. Akdis CA. Global Atlas of Asthma. Zurich: EAACI European Academy of Allergy and Clinical Immunology. Switzerland. 2011: 196.
  12. Wenzel S. Phenotypes & endotypes: Emerging concepts on asthma heterogeneity. EAACI Global atlas of Asthma. Zurich: European Academy of Allergy and Clinical Immunology. Switzerland. 2013: 34-36.
  13. Курбачёва ОМ, Павлова К.С. Фенотипы и эндотипы бронхиальной астмы: от патогенеза и клинической картины к выбору терапии. Российский Аллергологический Журнал. 2013; (1): 15-24
  14. Княжеская Н.П. Диагностика и лечение фенотипа бронхиальной астмы с повышенным метаболизмом лейкотриенов. Врач. 2013; (3): 82-86
  15. Bacharier L., Boner BA, Carlsen KH, Eigenmann PA, Frischer TM, Helms PJ. The European Pediatric Asthma Group Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy. 2008; 63: 5-34.
  16. Маркова ТП, Ким МН, Чувирова А.Г. Исмиген в комплексном лечении детей с бронхиальной астмой. Лекарственные средства в педиатрии. 2017; (96): 159-165
  17. Титова НД, Новикова В.И. Оценка иммунокоррегирующего эффекта глюкозаминилмурамилпептида при бронхиальной астме у детей. Иммунология, аллергология, инфектология. 2017; (1): 31-36
  18. Козлов ИГ, Колесникова НВ, Воронина ЕВ, Гурьянова СВ, Андронова Т.М. Глюкозаминилмурамилдипептид и другие агонисты рецепторов врожденного иммунитета в патогенетической терапии аллергических заболеваний. Аллергология и иммунология. 2013; (14): 281-287

Views

Abstract - 30

PDF (Russian) - 0

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2018 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies